• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吡咯里西啶生物碱诱导的肝窦阻塞综合征的钆塞酸增强肝胆期磁共振成像及与肝功能的关系。

Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function.

机构信息

Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

出版信息

Sci Rep. 2019 Feb 4;9(1):1231. doi: 10.1038/s41598-018-37775-1.

DOI:10.1038/s41598-018-37775-1
PMID:30718698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6362127/
Abstract

Hepatic sinusoidal obstruction syndrome (HSOS) can be caused by pyrrolizidine alkaloids(PAs)-containing herbals. In this study, the aim of our study was to investigate the imaging features of PAs-induced HSOS on gadoxetic acid-enhanced magnetic resonance imaging (MRI), susceptibility-weighted imaging(SWI) and T2* weighted imaging (T2* WI). We analyzed medical records and MR images of 28 PAs-induced HSOS patients enrolled from Feb, 2013, to Apr, 2017. Abnormal liver function was observed in most of the PAs-induced HSOS patients. Heterogeneity of liver parenchyma in hepatobillary phase (HBP) of gadoxetic acid-enhanced MR scan was observed in 100% of the PAs-induced HSOS patients. Distributional patterns of heterogeneous hypointensity were multifocal distribution (mild) in 4 patients (14.29%), multifocal distribution (severe) in 15 cases (53.57%), and diffuse distribution in 9 patients (32.14%). Hypointense in SWI and T2WI was observed in the patients of PAs-induced HSOS, and the distribution of hypointense in SWI and T2WI was similar to that of portal-venous phase of MR scan. The severity of heterogeneous hypointensity scored by volume fraction in hepatobillary phase of gadoxetic acid-enhanced MRI was positively correlated with PT and INR, the severity of hypointensity in HBP was a risk factor of death events. In conclusion: Heterogenous hypointensity of liver parenchyma was an imaging sign of hepatobillary phase in gadoxetic acid-enhanced MRI; thus, it will provide evidences for the diagnosis of PA-induced HSOS.

摘要

肝窦阻塞综合征(HSOS)可由含吡咯里西啶生物碱(PAs)的草药引起。本研究旨在探讨钆塞酸增强磁共振成像(MRI)、磁敏感加权成像(SWI)和 T2加权成像(T2WI)中 PAs 诱导的 HSOS 的影像学特征。我们分析了 2013 年 2 月至 2017 年 4 月期间收治的 28 例 PAs 诱导的 HSOS 患者的病历和 MRI 图像。大多数 PAs 诱导的 HSOS 患者肝功能异常。在所有 PAs 诱导的 HSOS 患者中,在肝胆期(HBP)的钆塞酸增强 MR 扫描中观察到肝实质不均匀。不均匀低信号的分布模式为 4 例(14.29%)为多灶性分布(轻度),15 例(53.57%)为多灶性分布(重度),9 例(32.14%)为弥漫性分布。PAs 诱导的 HSOS 患者在 SWI 和 T2WI 上均可见低信号,SWI 和 T2WI 上低信号的分布与 MR 扫描门静脉期相似。肝胆期钆塞酸增强 MRI 容积分数评分的不均匀低信号严重程度与 PT 和 INR 呈正相关,HBP 中的低信号严重程度是死亡事件的危险因素。总之,肝实质不均匀低信号是肝胆期钆塞酸增强 MRI 的影像学特征,可为 PA 诱导的 HSOS 的诊断提供依据。

相似文献

1
Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function.吡咯里西啶生物碱诱导的肝窦阻塞综合征的钆塞酸增强肝胆期磁共振成像及与肝功能的关系。
Sci Rep. 2019 Feb 4;9(1):1231. doi: 10.1038/s41598-018-37775-1.
2
Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome.吡咯里西啶生物碱诱导的肝窦阻塞综合征的 CT 增强扫描诊断性能。
Sci Rep. 2016 Nov 29;6:37998. doi: 10.1038/srep37998.
3
Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.血中吡咯-蛋白质加合物作为吡咯里西啶生物碱致肝窦阻塞综合征的诊断和预后指标
Drug Des Devel Ther. 2015 Aug 25;9:4861-8. doi: 10.2147/DDDT.S87858. eCollection 2015.
4
Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.吡咯里西啶生物碱诱导的肝窦阻塞综合征的临床特征、CT表现及病理结果:一项回顾性研究
BMC Gastroenterol. 2020 Feb 4;20(1):30. doi: 10.1186/s12876-020-1180-0.
5
Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.吡咯里西啶生物碱诱导的肝窦阻塞综合征:发病机制、临床表现、诊断、治疗和结局。
World J Gastroenterol. 2019 Jul 28;25(28):3753-3763. doi: 10.3748/wjg.v25.i28.3753.
6
Tusanqi and hepatic sinusoidal obstruction syndrome.土三七和肝窦阻塞综合征。
J Dig Dis. 2014 Mar;15(3):105-7. doi: 10.1111/1751-2980.12112.
7
Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.吡咯里西啶生物碱所致肝窦阻塞综合征的明确诊断。
J Dig Dis. 2012 Jan;13(1):33-9. doi: 10.1111/j.1751-2980.2011.00552.x.
8
Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.吡咯里西啶生物碱诱导的肝窦阻塞综合征临床管理专家共识。
J Gastroenterol Hepatol. 2019 Apr;34(4):634-642. doi: 10.1111/jgh.14612. Epub 2019 Feb 21.
9
First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans.首例吡咯里西啶生物碱 N-氧化物诱导的肝窦阻塞综合征的人类证据。
Arch Toxicol. 2017 Dec;91(12):3913-3925. doi: 10.1007/s00204-017-2013-y. Epub 2017 Jun 15.
10
Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.与食用菊三七相关的肝窦阻塞综合征。
J Hepatol. 2011 Apr;54(4):666-73. doi: 10.1016/j.jhep.2010.07.031. Epub 2010 Sep 22.

引用本文的文献

1
Radical total gastrectomy for gastric cancer complicated by hepatic sinusoidal obstruction syndrome: a case report.胃癌合并肝窦阻塞综合征的根治性全胃切除术:1例病例报告
Front Med (Lausanne). 2025 May 9;12:1544400. doi: 10.3389/fmed.2025.1544400. eCollection 2025.
2
Drug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives.药物性肝窦阻塞综合征:当前进展与未来展望
Arch Toxicol. 2025 Mar;99(3):835-850. doi: 10.1007/s00204-024-03950-9. Epub 2024 Dec 24.
3
MRI findings of newly present benign focal hepatic observations following chemotherapy: distinct features in early- and late-term follow-up.

本文引用的文献

1
Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease.吡咯里西啶生物碱相关肝静脉闭塞病的临床特征和治疗。
Liver Int. 2018 Oct;38(10):1867-1874. doi: 10.1111/liv.13684. Epub 2018 Feb 11.
2
CT Features of Hepatic Veno-occlusive Disease: A Meta-analysis.肝脏静脉闭塞病的 CT 特征:一项荟萃分析。
Acad Radiol. 2018 Mar;25(3):328-337. doi: 10.1016/j.acra.2017.10.012. Epub 2017 Nov 27.
3
Evaluation of motion correction for clinical dynamic contrast enhanced MRI of the liver.肝脏临床动态对比增强磁共振成像运动校正的评估
化疗后新出现的肝脏良性局灶性病变的MRI表现:早期和晚期随访中的不同特征
Eur Radiol. 2025 May;35(5):2783-2793. doi: 10.1007/s00330-024-11185-6. Epub 2024 Nov 12.
4
Clinicopathological characteristics and diagnosis of hepatic sinusoidal obstruction syndrome caused by Tusanqi - Case report and literature review.土三七致肝窦阻塞综合征的临床病理特征及诊断——病例报告并文献复习
Open Med (Wars). 2023 Jun 12;18(1):20230737. doi: 10.1515/med-2023-0737. eCollection 2023.
5
Difference between type 2 gastroesophageal varices and isolated fundic varices in clinical profiles and portosystemic collaterals.2型胃食管静脉曲张与孤立性胃底静脉曲张在临床特征和门体侧支循环方面的差异。
World J Clin Cases. 2022 Jun 16;10(17):5620-5633. doi: 10.12998/wjcc.v10.i17.5620.
6
Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid.血小板压积预测吡咯里西啶生物碱所致肝窦阻塞综合征患者预后的价值。
J Clin Lab Anal. 2022 Feb;36(2):e24240. doi: 10.1002/jcla.24240. Epub 2022 Jan 16.
7
Blood microRNA Signatures Serve as Potential Diagnostic Biomarkers for Hepatic Sinusoidal Obstruction Syndrome Caused by Containing Pyrrolizidine Alkaloids.血液微小RNA特征作为由含吡咯里西啶生物碱引起的肝窦阻塞综合征的潜在诊断生物标志物。
Front Pharmacol. 2021 Feb 19;12:627126. doi: 10.3389/fphar.2021.627126. eCollection 2021.
8
Prognostic factors for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: a multicenter study in China.吡咯里西啶生物碱诱导的肝窦阻塞综合征的预后因素:一项中国的多中心研究。
Ann Transl Med. 2021 Jan;9(1):11. doi: 10.21037/atm-20-731.
9
Liver injury in patients with COVID-19: clinical profiles, CT findings, the correlation of the severity with liver injury.COVID-19 患者的肝损伤:临床特征、CT 表现,与肝损伤严重程度的相关性。
Hepatol Int. 2020 Sep;14(5):733-742. doi: 10.1007/s12072-020-10087-1. Epub 2020 Sep 4.
10
Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.吡咯里西啶生物碱诱导的肝窦阻塞综合征的临床特征、CT表现及病理结果:一项回顾性研究
BMC Gastroenterol. 2020 Feb 4;20(1):30. doi: 10.1186/s12876-020-1180-0.
Phys Med Biol. 2017 Sep 12;62(19):7556-7568. doi: 10.1088/1361-6560/aa8848.
4
Use of Imaging to Predict Complete Response of Colorectal Liver Metastases after Chemotherapy: MR Imaging versus CT Imaging.使用影像学预测结直肠癌肝转移化疗后完全缓解:磁共振成像与 CT 成像的比较。
Radiology. 2017 Aug;284(2):423-431. doi: 10.1148/radiol.2017161619. Epub 2017 Mar 22.
5
Magnetic Resonance Imaging Findings in Patients With Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome.吡咯里西啶生物碱所致肝窦阻塞综合征患者的磁共振成像表现
Clin Gastroenterol Hepatol. 2017 Jun;15(6):955-957. doi: 10.1016/j.cgh.2017.01.009. Epub 2017 Jan 23.
6
Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome.吡咯里西啶生物碱诱导的肝窦阻塞综合征的 CT 增强扫描诊断性能。
Sci Rep. 2016 Nov 29;6:37998. doi: 10.1038/srep37998.
7
Sinusoidal obstruction syndrome.窦状隙阻塞综合征。
Clin Res Hepatol Gastroenterol. 2016 Sep;40(4):378-85. doi: 10.1016/j.clinre.2016.01.006. Epub 2016 Mar 30.
8
Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.肝细胞癌成像诊断的最新进展:钆塞酸二钠增强MRI的价值
Liver Cancer. 2016 Feb;5(1):67-87. doi: 10.1159/000367750. Epub 2015 Dec 18.
9
Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.血中吡咯-蛋白质加合物作为吡咯里西啶生物碱致肝窦阻塞综合征的诊断和预后指标
Drug Des Devel Ther. 2015 Aug 25;9:4861-8. doi: 10.2147/DDDT.S87858. eCollection 2015.
10
Tusanqi-Related Sinusoidal Obstruction Syndrome in China: A Systematic Review of the Literatures.中国土三七相关肝窦阻塞综合征:文献系统评价
Medicine (Baltimore). 2015 Jun;94(23):e942. doi: 10.1097/MD.0000000000000942.